Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics is a clinical-stage biotechnology company developing Decoy20, a systemically administered immunotherapy. For the six months ended June 30, 2025, the company reported a net loss of $9.76 million and used approximately $9.1 million of cash in operations. Cash and cash equivalents were $6.16 million at period end, which management estimates funds operations into the fourth quarter of 2025 under the current plan. The company had an accumulated deficit of $70.2 million and recorded a stockholders equity (deficit) of $(1.67) million as of June 30, 2025, with management stating there is substantial doubt about the companys ability to continue as a going concern.
The increase in research and development expense to $4.98 million for the six months (up 50.6% year-over-year) was driven mainly by higher clinical trial costs for the Phase 1 Decoy20 program. Management completed several financings during the period: a January 2025 private placement raising approximately $2.0 million net, sales under a Standby Equity Purchase Agreement (SEPA) that generated approximately $1.75 million net, and a June 2025 private placement of convertible notes with gross proceeds of approximately $5.7 million (measured at fair value of $6.50 million on June 30). The company effected a 1-for-28 reverse stock split to regain Nasdaq minimum bid price compliance, and subsequent conversion of the Notes in July 2025 and related warrant issuances resulted in the company satisfying the Nasdaq minimum stockholders equity requirement of $2.5 million.
Indaptus Therapeutics, Inc. furnished an earnings-related update by issuing a press release with its financial results for the quarter ended June 30, 2025. The company submitted this release as an exhibit to a current report, making the information available to the market while stating that it is furnished rather than filed under securities law. The report is signed on behalf of Indaptus Therapeutics by its Chief Financial Officer, Nir Sassi.
Indaptus Therapeutics (Nasdaq: INDP) filed an 8-K disclosing that its board executed a 1-for-28 reverse stock split of issued and outstanding common shares.
The Certificate of Amendment was filed in Delaware on 26 June 2025 and became effective at 5:00 p.m. ET. Split-adjusted trading begins 27 June 2025. Every twenty-eight shares automatically converted into one; no change to the $0.01 par value.
- No fractional shares: holders receive cash based on the 26 June Nasdaq closing price.
- All outstanding options and warrants were proportionally adjusted.
- Post-split shares continue to trade under ticker INDP; new CUSIP: 45339J 204.
- VStock Transfer, LLC will serve as exchange agent.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) has called a Special Meeting of Stockholders for July 25, 2025 at 10:00 a.m. Eastern Time at its New York headquarters. The record date is June 16, 2025, with 16,034,444 common shares outstanding and entitled to one vote each. The Board is soliciting proxies through this DEF 14A to obtain shareholder approval for two key proposals tied to an ongoing Rule 506(c) private placement of convertible notes and warrants.
- Issuance Proposal (Nasdaq Rule 5635(d)): Authorizes the issuance of common stock upon (i) conversion of the private-placement convertible notes and (ii) exercise of a series of warrants (common, pre-funded and placement-agent) arising from the same financing.
- Related-Party Proposal (Nasdaq Rule 5635(c)): Approves the issuance of common stock to the Company’s Chief Executive Officer and Director upon conversion of any such notes and upon exercise of related warrants that may be allotted to him.
Approval is required to comply with Nasdaq’s shareholder-approval rules because (i) the aggregate share issuance could exceed 20% of outstanding equity (Rule 5635(d)) and (ii) a director/CEO is a potential investor in the financing (Rule 5635(c)). Shareholders may vote by telephone, Internet, mail or in person; proxies are revocable, and in-person voting is permitted even after a proxy is submitted. Attendees must pre-register with building security and present photo ID; the Company may shift to a virtual format via a future Form 8-K if necessary.
Aside from routine matters and potential adjournments, no further business is scheduled. The Board recommends shareholders vote FOR each proposal.
Indaptus Therapeutics, Inc. (CIK 0001857044) filed a Form D notice with the SEC to report a new exempt offering of securities. The biotechnology company, incorporated in Delaware in 2021 and operating from 3 Columbus Circle, New York, is claiming the Rule 506(c) exemption, which allows general solicitation provided that all purchasers are accredited investors.
Offering details:
- Date of first sale: 12 June 2025
- Securities offered: (i) Options, warrants, or other rights to acquire another security and (ii) the underlying securities issuable upon exercise of those rights
- Minimum investment: $0 USD, indicating flexibility for investor entry size
- Offering duration: The issuer does not expect the offering to last more than one year
- Issuer size: The company elected “Decline to Disclose” for both revenue and asset ranges
Intermediary & solicitation: Paulson Investment Company, LLC (CRD 000005670) is identified as the broker-dealer. Solicitation will occur in multiple U.S. states (e.g., CA, CO, FL) and in foreign jurisdictions.
Management & directors: The filing lists key executives and directors, including CEO Jeffrey A. Meckler, CFO Nir Sassi, and several directors such as Roger J. Pomerantz and Hila Karah. No promoters are designated.
Other disclosures: • The offering is not tied to a business-combination transaction.
• No sales compensation recipients beyond Paulson Investment Company are disclosed.
• The issuer is categorised under the “Pharmaceuticals” industry segment.
Information gaps: Items concerning total amount offered, sold, and remaining are not present in the excerpt, limiting visibility into potential dilution and capital inflow.